The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma.
Jonathan E. Rosenberg
No relevant relationships to disclose
Eliezer Mendel Van Allen
No relevant relationships to disclose
Kent William Mouw
No relevant relationships to disclose
Philip H. Kim
No relevant relationships to disclose
Nikhil Wagle
Consultant or Advisory Role - Foundation Medicine
Stock Ownership - Foundation Medicine
Hikmat Al-Ahmadie
No relevant relationships to disclose
Cong Zhu
No relevant relationships to disclose
Irina Ostrovnaya
No relevant relationships to disclose
Gopa Iyer
No relevant relationships to disclose
Sabina Signoretti
No relevant relationships to disclose
Victor E. Reuter
No relevant relationships to disclose
Gad Getz
No relevant relationships to disclose
Philip W. Kantoff
No relevant relationships to disclose
Bernard H. Bochner
No relevant relationships to disclose
Toni K. Choueiri
No relevant relationships to disclose
Dean F. Bajorin
No relevant relationships to disclose
David B. Solit
No relevant relationships to disclose
Stacey B. Gabriel
No relevant relationships to disclose
Alan D. D'Andrea
No relevant relationships to disclose
Levi A. Garraway
Consultant or Advisory Role - Foundation Medicine
Stock Ownership - Foundation Medicine